Αναστασία Κωνσταντινίδου
ΚΩΝΣΤΑΝΤΙΝΙΔΟΥ ΑΝΑΣΤΑΣΙΑ
CONSTANTINIDOU ANASTASIA
...
-
Medical School
-
-
-
-
-
-

Προσωπικό Προφίλ

 
Dr Anastasia Constantinidou graduated with a first class from the Medical School of the National and Kapodistrian University in Athens Greece (MD). She gained Membership of the Royal College of Physicians (MRCP) in the UK and she subsequently completed her specialist clinical training in Internal Medicine (2006) and her specialist clinical training in Medical Oncology (CCT) at the Royal Marsden Hospital in London (2011). She gained an MSc in Oncology (Merit) from the University of London and she was awarded a Wellcome Trust Fellowship for laboratory research in Molecular Pathology for her four-year full time PhD studies at the Institute of Cancer Research, University of London.
 

Her basic science research has focused on the identification of genes involved in the process of cell differentiation as novel targets in cancer therapeutics with emphasis on epigenetics. Her clinical and translational research expertise is based on first-hand experience in running over 80 UK, European and international clinical and translational trials as a principal or co-investigator including first in human (phase I) clinical trials.

She has been awarded a number of fellowships throughout her career including the Hellenic Society of Medical Oncology Clinical Training Fellowship and the ECCO-AACR-EORTC-ESMO Fellowship in Methods in Clinical Cancer Research Workshop as well as grants from the Wellcome Trust UK, the Sarcoma UK, the Research Promotion Foundation (RPF Cyprus), the Horizon 2020 Research and Innovation Framework European Programme. She is a member of the National (Cyprus) Bioethics Committee and the National (Cyprus) Committee for Laboratory Animal Welfare since 2018.

Through competitive selection, she has presented her work in many international conferences including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) and the Connective Tissue Oncology Society (CTOS) annual conferences for over a decade. She has authored publications in high impact factor peer-reviewed journals including the Lancet Oncology, the Nature Reviews Clinical Oncology, the Annals of Oncology, the European Journal of Cancer, the British Journal of Cancer and Pharmacology & Therapeutics. Current h-index is 16 (google scholar).

She serves as a reviewer and an editorial board member in many oncology and medical journals. She has been an invited speaker and chair on topics related to her research and clinical work nationally (UK, Cyprus) and internationally. She is an invited organizing committee member in the 2019 annual ESMO Asia and the 2020 annual ESMO conferences. She is a Faculty member of the European School of Oncology for oncology trainees and junior oncologists.

Ø  translational research applications with emphasis on the utilization of laboratory discoveries related to gene expression to identify new targets for anticancer therapy and biomarkers to guide response assessment in the context of personalized and precision medicine

Ø  early phase clinical trials of novel targeted agents in cancer

Ø  the role of genetic and epigenetic changes in cancer development and progression and  the potential of these changes to become targets for therapy

Ø  functional imaging in humans and its role in the assessment of biological changes during disease progression



Selected peer reviewed publications

  • Sebio A, Constantinidou A, Benson C, Antoniou G, Messiou C, Miah A, Zaidi S, Petruckevitch A, Al-Muderis O, Thway K, VAN DER Graaf WT, Jones RL. Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. Anticancer Res. 2019 Jan;39(1):347-351.
  • Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing. Viruses. 2018 Dec 19;10(12)
  • A. Constantinidou, C. Alifieris, D. T Trafalis. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A prosperous new era in cancer active immunotherapy. Pharmacology & Therapeutics. 2018 Sep 28. pii: S0163-7258(18)30173-6.
  • Owen C, Constantinidou A, Miah AB, Thway K, Fisher C, Benson C, Zaidi S, Messiou C, Van Der Graaf WTA, Jones RL. Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management. Anticancer Res. 2018 Sep;38(9):5275-5282.
  • Constantinidou A, Jones L R. Systemic Therapy in RPS Management. J Surg Oncol. 2018 Jan;117(1):87-92.
  • Constantinidou A, van der Graaf WTA. The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma. Eur J Cancer. 2017 Oct;84:257-261. doi: 10.1016/j.ejca.2017.07.043. Epub 2017 Aug 23
  • Petrou A, Constantinidou A, Kontos M, Papalampros A, Moris D, Bakoyiannis C, Neofytou K, Kourounis G, Felekouras E. Comprehensive Surgical Treatment as the Mainstay of Management in Retroperitoneal Sarcomas: Retrospective Study from Two Non-sarcoma Specialist Centers. Anticancer Res. 2017 Apr;37(4):2025-2031
  • Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, van der Graaf WT, Jones RL. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017 Jan;13(1):93-107
  • Desar IM, Constantinidou A, Kaal SE, Jones RL, van der Graaf WT. Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin. Cancer Manag Res. 2016 Aug 17;8:95-104.
  • A Constantinidou, I R Judson. Systemic treatment of liposarcomas: light at the end of the tunnel? Journal of Oncology Practice (JOP) March 2016.
  • Noujaim J, Constantinidou A, Messiou C, Thway K, Miah A, Benson C, Judson I, Jones RL. Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. Am J Clin Oncol. 2015 Oct 29.
  • Sanfilippo R, Dileo P, Blay JY, Constantinidou A, Le Cesne A, Benson C, Vizzini L, Contu M, Baldi GG, Dei Tos AP, Casali PG. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anticancer Drugs. 2015 Jul;26(6):678-81.
  • Constantinidou A, Pollack SM, Jones RL. Management and outcome of metastatic clear cell sarcoma. Eur J Surg Oncol. 2014 Oct;40(10):1383.
  • J Martin-Liberal, S Alam, A Constantinidou, C Fisher, K Khabra, C Messiou, D Olmos, S Mitchell, O Al-Muderis, A Miah, M Linch, R L. Jones, M Scurr, I Judson, and C Benson. Clinical activity and tolerability of a 14-day infusional ifosfamide schedule in soft-tissue sarcoma. Hindawi Publishing Corporation. Sarcoma. 2013: 868973.
  • A Constantinidou, A Miah, S Pollack, RL Jones. New Drugs and clinical trial design in advanced Sarcoma: have we made any progress? Future Oncol. 2013 Oct;9(10):1409-11. doi: 10.2217/fon.13.132. Epub 2013 Jul 15.
  • AJ Bathan*, A Constantinidou*, SM Pollack, RL Jones. Diagnosis, prognosis, and management of Leiomyosarcoma: recognition of anatomic variants. Curr Opin Oncol. 2013 Jul;25(4):384-9.
  • Constantinidou A, Pollack S, Loggers E, Rodler E, Jones RL. The evolution of systemic therapy in sarcoma. Expert Rev Anticancer Ther. 2013 Feb;13(2):211-23.
  • B Sharma, A Martin, S Stanway, S R D Johnston and A Constantinidou. Imaging in oncology - over a century of advances. Nat Rev Clin Oncol. 2012 Dec;9(12):728-37.
  • A Constantinidou, SM Pollack, RL Jones. MDM2 inhibition in well- and de-differentiated liposarcoma: A step in the right direction. Lancet Oncol. 2012 Nov;13(11):1070-1.
  • A Constantinidou, D Cunningham, F Shurmahi, U Asghar, Y Barbachano, A Khan, S Mudan, S Rao, I Chau. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection. Clin Colorectal Cancer. 2013 Mar;12(1):15-22.
  • R L Jones, A Constantinidou, J S Reis-Filho. Molecular Classification of Breast Cancer. Surg Pathol Clin. 2012 Sep;5(3):701-17.
  • Jones RL, Constantinidou A. The efficacy of caffeine-potentiated chemotherapy in clear cell sarcoma. Int J Clin Oncol. 2013 Apr;18(2):356.
  • Constantinidou A, Smith I. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer? Breast 2011 Oct; 20 Suppl 3:S158-61.
  • Constantinidou A, Jones R L, D Olmos D, Thway K, Fisher C, Al-Muderis O, Judson I. Conventional anthracycline-based chemotherapy has limited efficacy in Solitary Fibrous Tumour. Acta Oncol. 2012 Apr;51(4):550-4.
  • Waddell T*, Kotsori A*, Constantinidou A, Yousaf N, Ashley S, Parton M, Allen M, Starling N, Papadopoulos P, O'Brien M, Smith I, Johnston S. Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience. Br J Cancer. 2011 May 24;104(11):1675-9.
  • RL Jones, A Constantinidou, D Olmos, K Thway, C Fisher, O Al-Muderis, M Scurr, I Judson. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012 Aug;35(4):351-7.
  • A Constantinidou, R L Jones, M Scurr, O Al-Muderis, I Judson. Aggressive fibromatosis: effective palliation with chemotherapy. Acta Oncol. 2011 Apr;50(3):455-61.
  • A. Constantinidou, R. L. Jones, Jorge S Reis-Filho. Beyond triple-negative breast cancer - the need to define new subtypes. Expert Rev of Anticancer Ther. 2010 Aug; 10(8): 1197-213.
  • A Constantinidou, A Martin, B Sharma, S Johnston. Positron Emission Tomography/ Computed Tomography in the management of recurrent/ metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol. 2011 Feb 22 ;(2): 307-314.
  • A Constantinidou, S B Popat. Advanced non-small cell lung cancer: Developments in therapy have changed diagnostic practice. MIMS Oncology Vol 4, Issue 2 June 2010.
  • RL Jones, A Constantinidou, O Al-Muderis, K Thway, S Ashley, M Scurr, D R D’Adamo, ML Keohan, RG Maki, I R Judson. Chemotherapy in Clear Cell Sarcoma. Med Oncol. 2011 Sep;28(3):859-63.
  • A. Constantinidou, S.A. Afuwape, L. Linsell, T. Hung, K. Acland, C. Healy, A-J Ramirez, M. Harries. Informational needs of patients with melanoma and their views on the utility of investigative tests. Int J Clin Pract. 2009 Nov;63(11):1595-600.
  • A. Constantinidou, R. L. Jones, M. Scurr, O. Al-Muderis, I. Judson. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009 Nov;45(17):2930-4
  • Constantinidou A, Hofman M, O’Doherty M, Acland KM, Healy C, Harries M. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Res. 2008 Feb; 18(1):56-60.
  • Hofman MS, Constantinidou A, Acland K, Healy C, Harries M, O' Doherty M; Melanoma Group. Assessing response to chemotherapy in metastatic melanoma with FDG PET: Early experience. Nucl Med Commun. 2007 Dec; 28(12):902-6.
 

Selected Book chapters and Guidelines

  • 2016: I.M.E. Desar*, A. Constantinidou*, W.T.A. van der Graaf. ESMO Handbook, Chapter: Rare Cancers.
  • 2012: Robin L Jones, Anastasia Constantinidou, Jorge S Reis-Filho. Molecular classification of breast cancer. Surgical Pathology Clinics. Breast Pathology: Diagnosis and Insights. Volume 5, Issue 3, Pages 701-717. Saunders, Division of Elsevier.
  • 2011: Anastasia Constantinidou, Robin L Jones, Jorge S Reis-Filho. Advances in the management of triple-negative breast cancer: Chapter 2: Diagnosis and Pathology. Future Medicine.
  • 2010: A Constantinidou, M Scurr, I Judson. Desmoid Tumour: clinical presentations. Springer Science.
  • 2009: J Larkin, A Constantinidou. Monograph for the BMJ: Guidelines for the management of tumour lysis syndrome.
 

Selected Published Abstracts 

  • D Collins, A Constantinidou, R Sundar, M Chenard-Poirier, T A Yap, U Banerji, J S. De Bono, J S Lopez, and N Tunariu. Patterns of metastases in malignant pleural mesothelioma in the modern era: Redefining the spread of an old disease. J Clin Oncol 2017 35:15_suppl 8556-8556. 
  • T A. Yap, J N. Winter, J P. Leonard, V Ribrag, A Constantinidou, et al. A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM). Blood Dec 2016 128:420.
  • A. Constantinidou, J. Selfe, T. Khin, S. Popov, E. Missiaglia, E. Aladowicz, R. Al-Saadi, D. Olmos, R. Jones, D. Strauss, A. Hayes, W. van der Graaf, I. Judson, J. Shipley. Epigenetic modulation in well differentiated (WD) and dedifferentiated (DD) liposarcoma (LPS): a novel therapeutic approach. Ann Oncol (2016 Oct) 27 (suppl 6): doi:10.1093/annonc/mdw388.04.
  • V Michalarea, A Constantinidou, M Guardascione, N Diamantis, R Perez, K Rihawi, E Geuna, J Lopez, S B Kaye, T A. Yap, J S. De Bono, U Banerji, L R Molife, N Tunariu. Ultrasound guided biopsies in phase I trials: Single center experience of 350 consecutive cases. J Clin Oncol 34, 2016 (suppl; abstr 11579).
  • N Diamantis, S Harris, A Constantinidou, V Michalarea, M Fontes, M Luken, T Avaiya, A Petruckevitch, D Flohr, J Hanwell, D Papadatos-Pastos, J Lopez, T Yap, J S. De Bono, and U Banerji. Incidence, severity and factors associated with diarrhoea in phase I oncology studies: experience of 1002 consecutive cases. Journal of Clinical Oncology 2016 34:15_suppl, 2568-2568 
  • A. Constantinidou, D. Krikelis, D. Olmos, M Scurr, RL Jones, S Ashley, IR Judson. Early assessment of MCV can predict clinical outcome in patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib. June 12: ASCO Annual Meeting, Chicago, Illinois, USA. J Clin Oncol 30: 2012 (suppl; abstr 10086)
  • R. Sanfilippo, A. Constantinidou, R. Bertulli, P. Coco, E. Fumagalli, M. Scurr, C. Morosi, S. Pilotti, I. R. Judson, P. G. Casali. Well-differentiated/dedifferentiated liposarcoma (WD/DD) and myxoid round cell/liposarcoma (MRCL) have differential sensitivity to high dose ifosfamide: combined analysis from two european referral institutions. June 11: ASCO Annual Meeting, Chicago, Illinois, USA. J Clin Oncol 29: 2011 (suppl; abstr 10023)
  • A Constantinidou, RL Jones, O Al-Muderis, K Thway, S Ashley, M Scurr, D R D’Adamo, ML Keohan, RG Maki, I R Judson. Chemotherapy in Clear Cell Sarcoma. ASCO Annual Meeting. Abstract No: 10098. Chicago, Illinois, USA, J Clin Oncol 28:15s, June 2010 (suppl; abstr 10098).
  • L. M. Pickering, A. Constantinidou, J. M. Larkin, S. A. Sohaib, P. Khatri, P. D. Nathan, A. Vinayan, T. Ferguson, S. St. Rose, M. E. Gore. Sunitinib treatment for longer than 2 years for renal cell carcinoma. ASCO Annual Meeting, Chicago, Illinois, USA, J Clin Oncol 28, June 2010 (suppl; abstr e15099)
  • A Constantinidou, R L Jones, M Scurr, O Al-Muderis, I Judson. The role of chemotherapy in aggressive fibromatosis. Sept 09: ESMO Berlin, Germany EJC suppl abstract book Vol 7 (2): 596, abstract no 9421
  • A Constantinidou, M Scurr, R Jones, O Al-Muderis, I Judson. Treatment of aggressive fibromatosis with pegylated liposomal doxorubicin: The Royal Marsden Hospital experience. ASCO Annual Meeting, Orlando, Florida, USA, J Clin Oncol 27:15s, May 2009 (suppl; abstr 10519)
  • A Constantinidou, SA Afuwape, T Hung, K Acland, C Healy, A-J Ramirez, M Harries. The role of PET scanning and sentinel node biopsy in melanoma: the patients’ perspective. Sept 08: ESMO Stockholm, Sweden, Annals of Oncology 19 (suppl 8): viii239 - viii246, 2008, abstract no 780P
 

Profile Information

 
Dr Anastasia Constantinidou graduated with a first class from the Medical School of the National and Kapodistrian University in Athens Greece (MD). She gained Membership of the Royal College of Physicians (MRCP) in the UK and she subsequently completed her specialist clinical training in Internal Medicine (2006) and her specialist clinical training in Medical Oncology (CCT) at the Royal Marsden Hospital in London (2011). She gained an MSc in Oncology (Merit) from the University of London and she was awarded a Wellcome Trust Fellowship for laboratory research in Molecular Pathology for her four-year full time PhD studies at the Institute of Cancer Research, University of London.
 
Her basic science research has focused on the identification of genes involved in the process of cell differentiation as novel targets in cancer therapeutics with emphasis on epigenetics. Her clinical and translational research expertise is based on first-hand experience in running over 80 UK, European and international clinical and translational trials as a principal or co-investigator including first in human (phase I) clinical trials.
 
She has been awarded a number of fellowships throughout her career including the Hellenic Society of Medical Oncology Clinical Training Fellowship and the ECCO-AACR-EORTC-ESMO Fellowship in Methods in Clinical Cancer Research Workshop as well as grants from the Wellcome Trust UK, the Sarcoma UK, the Research Promotion Foundation (RPF Cyprus), the Horizon 2020 Research and Innovation Framework European Programme. She is a member of the National (Cyprus) Bioethics Committee and the National (Cyprus) Committee for Laboratory Animal Welfare since 2018.
 
Through competitive selection, she has presented her work in many international conferences including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO) and the Connective Tissue Oncology Society (CTOS) annual conferences for over a decade. She has authored publications in high impact factor peer-reviewed journals including the Lancet Oncology, the Nature Reviews Clinical Oncology, the Annals of Oncology, the European Journal of Cancer, the British Journal of Cancer and Pharmacology & Therapeutics. Current h-index is 16 (google scholar).
 
She serves as a reviewer and an editorial board member in many oncology and medical journals. She has been an invited speaker and chair on topics related to her research and clinical work nationally (UK, Cyprus) and internationally. She is an invited organizing committee member in the 2019 annual ESMO Asia and the 2020 annual ESMO conferences. She is a Faculty member of the European School of Oncology for oncology trainees and junior oncologists.
 
Ø  translational research applications with emphasis on the utilization of laboratory discoveries related to gene expression to identify new targets for anticancer therapy and biomarkers to guide response assessment in the context of personalized and precision medicine

Ø  early phase clinical trials of novel targeted agents in cancer

Ø  the role of genetic and epigenetic changes in cancer development and progression and  the potential of these changes to become targets for therapy

Ø  functional imaging in humans and its role in the assessment of biological changes during disease progression

Selected peer reviewed publications

  • Sebio A, Constantinidou A, Benson C, Antoniou G, Messiou C, Miah A, Zaidi S, Petruckevitch A, Al-Muderis O, Thway K, VAN DER Graaf WT, Jones RL. Gemcitabine Re-challenge in Metastatic Soft Tissue Sarcomas: A Therapeutic Option for Selected Patients. Anticancer Res. 2019 Jan;39(1):347-351.
  • Chrysostomou AC, Stylianou DC, Constantinidou A, Kostrikis LG. Cervical Cancer Screening Programs in Europe: The Transition Towards HPV Vaccination and Population-Based HPV Testing. Viruses. 2018 Dec 19;10(12)
  • A. Constantinidou, C. Alifieris, D. T Trafalis. Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A prosperous new era in cancer active immunotherapy. Pharmacology & Therapeutics. 2018 Sep 28. pii: S0163-7258(18)30173-6.
  • Owen C, Constantinidou A, Miah AB, Thway K, Fisher C, Benson C, Zaidi S, Messiou C, Van Der Graaf WTA, Jones RL. Synovial Sarcoma of the Thyroid Gland, Diagnostic Pitfalls and Clinical Management. Anticancer Res. 2018 Sep;38(9):5275-5282.
  • Constantinidou A, Jones L R. Systemic Therapy in RPS Management. J Surg Oncol. 2018 Jan;117(1):87-92.
  • Constantinidou A, van der Graaf WTA. The fate of new fosfamides in phase III studies in advanced soft tissue sarcoma. Eur J Cancer. 2017 Oct;84:257-261. doi: 10.1016/j.ejca.2017.07.043. Epub 2017 Aug 23
  • Petrou A, Constantinidou A, Kontos M, Papalampros A, Moris D, Bakoyiannis C, Neofytou K, Kourounis G, Felekouras E. Comprehensive Surgical Treatment as the Mainstay of Management in Retroperitoneal Sarcomas: Retrospective Study from Two Non-sarcoma Specialist Centers. Anticancer Res. 2017 Apr;37(4):2025-2031
  • Szucs Z, Thway K, Fisher C, Bulusu R, Constantinidou A, Benson C, van der Graaf WT, Jones RL. Molecular subtypes of gastrointestinal stromal tumors and their prognostic and therapeutic implications. Future Oncol. 2017 Jan;13(1):93-107
  • Desar IM, Constantinidou A, Kaal SE, Jones RL, van der Graaf WT. Advanced soft-tissue sarcoma and treatment options: critical appraisal of trabectedin. Cancer Manag Res. 2016 Aug 17;8:95-104.
  • A Constantinidou, I R Judson. Systemic treatment of liposarcomas: light at the end of the tunnel? Journal of Oncology Practice (JOP) March 2016.
  • Noujaim J, Constantinidou A, Messiou C, Thway K, Miah A, Benson C, Judson I, Jones RL. Successful Ifosfamide Rechallenge in Soft-Tissue Sarcoma. Am J Clin Oncol. 2015 Oct 29.
  • Sanfilippo R, Dileo P, Blay JY, Constantinidou A, Le Cesne A, Benson C, Vizzini L, Contu M, Baldi GG, Dei Tos AP, Casali PG. Trabectedin in advanced synovial sarcomas: a multicenter retrospective study from four European institutions and the Italian Rare Cancer Network. Anticancer Drugs. 2015 Jul;26(6):678-81.
  • Constantinidou A, Pollack SM, Jones RL. Management and outcome of metastatic clear cell sarcoma. Eur J Surg Oncol. 2014 Oct;40(10):1383.
  • J Martin-Liberal, S Alam, A Constantinidou, C Fisher, K Khabra, C Messiou, D Olmos, S Mitchell, O Al-Muderis, A Miah, M Linch, R L. Jones, M Scurr, I Judson, and C Benson. Clinical activity and tolerability of a 14-day infusional ifosfamide schedule in soft-tissue sarcoma. Hindawi Publishing Corporation. Sarcoma. 2013: 868973.
  • A Constantinidou, A Miah, S Pollack, RL Jones. New Drugs and clinical trial design in advanced Sarcoma: have we made any progress? Future Oncol. 2013 Oct;9(10):1409-11. doi: 10.2217/fon.13.132. Epub 2013 Jul 15.
  • AJ Bathan*, A Constantinidou*, SM Pollack, RL Jones. Diagnosis, prognosis, and management of Leiomyosarcoma: recognition of anatomic variants. Curr Opin Oncol. 2013 Jul;25(4):384-9.
  • Constantinidou A, Pollack S, Loggers E, Rodler E, Jones RL. The evolution of systemic therapy in sarcoma. Expert Rev Anticancer Ther. 2013 Feb;13(2):211-23.
  • B Sharma, A Martin, S Stanway, S R D Johnston and A Constantinidou. Imaging in oncology - over a century of advances. Nat Rev Clin Oncol. 2012 Dec;9(12):728-37.
  • A Constantinidou, SM Pollack, RL Jones. MDM2 inhibition in well- and de-differentiated liposarcoma: A step in the right direction. Lancet Oncol. 2012 Nov;13(11):1070-1.
  • A Constantinidou, D Cunningham, F Shurmahi, U Asghar, Y Barbachano, A Khan, S Mudan, S Rao, I Chau. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection. Clin Colorectal Cancer. 2013 Mar;12(1):15-22.
  • R L Jones, A Constantinidou, J S Reis-Filho. Molecular Classification of Breast Cancer. Surg Pathol Clin. 2012 Sep;5(3):701-17.
  • Jones RL, Constantinidou A. The efficacy of caffeine-potentiated chemotherapy in clear cell sarcoma. Int J Clin Oncol. 2013 Apr;18(2):356.
  • Constantinidou A, Smith I. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer? Breast 2011 Oct; 20 Suppl 3:S158-61.
  • Constantinidou A, Jones R L, D Olmos D, Thway K, Fisher C, Al-Muderis O, Judson I. Conventional anthracycline-based chemotherapy has limited efficacy in Solitary Fibrous Tumour. Acta Oncol. 2012 Apr;51(4):550-4.
  • Waddell T*, Kotsori A*, Constantinidou A, Yousaf N, Ashley S, Parton M, Allen M, Starling N, Papadopoulos P, O'Brien M, Smith I, Johnston S. Trastuzumab beyond progression in HER2-positive advanced breast cancer: The Royal Marsden experience. Br J Cancer. 2011 May 24;104(11):1675-9.
  • RL Jones, A Constantinidou, D Olmos, K Thway, C Fisher, O Al-Muderis, M Scurr, I Judson. Role of palliative chemotherapy in advanced epithelioid sarcoma. Am J Clin Oncol. 2012 Aug;35(4):351-7.
  • A Constantinidou, R L Jones, M Scurr, O Al-Muderis, I Judson. Aggressive fibromatosis: effective palliation with chemotherapy. Acta Oncol. 2011 Apr;50(3):455-61.
  • A. Constantinidou, R. L. Jones, Jorge S Reis-Filho. Beyond triple-negative breast cancer - the need to define new subtypes. Expert Rev of Anticancer Ther. 2010 Aug; 10(8): 1197-213.
  • A Constantinidou, A Martin, B Sharma, S Johnston. Positron Emission Tomography/ Computed Tomography in the management of recurrent/ metastatic breast cancer: a large retrospective study from the Royal Marsden Hospital. Ann Oncol. 2011 Feb 22 ;(2): 307-314.
  • A Constantinidou, S B Popat. Advanced non-small cell lung cancer: Developments in therapy have changed diagnostic practice. MIMS Oncology Vol 4, Issue 2 June 2010.
  • RL Jones, A Constantinidou, O Al-Muderis, K Thway, S Ashley, M Scurr, D R D’Adamo, ML Keohan, RG Maki, I R Judson. Chemotherapy in Clear Cell Sarcoma. Med Oncol. 2011 Sep;28(3):859-63.
  • A. Constantinidou, S.A. Afuwape, L. Linsell, T. Hung, K. Acland, C. Healy, A-J Ramirez, M. Harries. Informational needs of patients with melanoma and their views on the utility of investigative tests. Int J Clin Pract. 2009 Nov;63(11):1595-600.
  • A. Constantinidou, R. L. Jones, M. Scurr, O. Al-Muderis, I. Judson. Pegylated liposomal doxorubicin, an effective, well-tolerated treatment for refractory aggressive fibromatosis. Eur J Cancer. 2009 Nov;45(17):2930-4
  • Constantinidou A, Hofman M, O’Doherty M, Acland KM, Healy C, Harries M. Routine positron emission tomography and positron emission tomography/computed tomography in melanoma staging with positive sentinel node biopsy is of limited benefit. Melanoma Res. 2008 Feb; 18(1):56-60.
  • Hofman MS, Constantinidou A, Acland K, Healy C, Harries M, O' Doherty M; Melanoma Group. Assessing response to chemotherapy in metastatic melanoma with FDG PET: Early experience. Nucl Med Commun. 2007 Dec; 28(12):902-6.
 

Selected Book chapters and Guidelines

  • 2016: I.M.E. Desar*, A. Constantinidou*, W.T.A. van der Graaf. ESMO Handbook, Chapter: Rare Cancers.
  • 2012: Robin L Jones, Anastasia Constantinidou, Jorge S Reis-Filho. Molecular classification of breast cancer. Surgical Pathology Clinics. Breast Pathology: Diagnosis and Insights. Volume 5, Issue 3, Pages 701-717. Saunders, Division of Elsevier.
  • 2011: Anastasia Constantinidou, Robin L Jones, Jorge S Reis-Filho. Advances in the management of triple-negative breast cancer: Chapter 2: Diagnosis and Pathology. Future Medicine.
  • 2010: A Constantinidou, M Scurr, I Judson. Desmoid Tumour: clinical presentations. Springer Science.
  • 2009: J Larkin, A Constantinidou. Monograph for the BMJ: Guidelines for the management of tumour lysis syndrome.

 

Selected Published Abstracts 

  • D Collins, A Constantinidou, R Sundar, M Chenard-Poirier, T A Yap, U Banerji, J S. De Bono, J S Lopez, and N Tunariu. Patterns of metastases in malignant pleural mesothelioma in the modern era: Redefining the spread of an old disease. J Clin Oncol 2017 35:15_suppl 8556-8556. 
  • T A. Yap, J N. Winter, J P. Leonard, V Ribrag, A Constantinidou, et al. A Phase I Study of GSK2816126, an Enhancer of Zeste Homolog 2(EZH2) Inhibitor, in Patients (pts) with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Other Non-Hodgkin Lymphomas (NHL), Transformed Follicular Lymphoma (tFL), Solid Tumors and Multiple Myeloma (MM). Blood Dec 2016 128:420.
  • A. Constantinidou, J. Selfe, T. Khin, S. Popov, E. Missiaglia, E. Aladowicz, R. Al-Saadi, D. Olmos, R. Jones, D. Strauss, A. Hayes, W. van der Graaf, I. Judson, J. Shipley. Epigenetic modulation in well differentiated (WD) and dedifferentiated (DD) liposarcoma (LPS): a novel therapeutic approach. Ann Oncol (2016 Oct) 27 (suppl 6): doi:10.1093/annonc/mdw388.04.
  • V Michalarea, A Constantinidou, M Guardascione, N Diamantis, R Perez, K Rihawi, E Geuna, J Lopez, S B Kaye, T A. Yap, J S. De Bono, U Banerji, L R Molife, N Tunariu. Ultrasound guided biopsies in phase I trials: Single center experience of 350 consecutive cases. J Clin Oncol 34, 2016 (suppl; abstr 11579).
  • N Diamantis, S Harris, A Constantinidou, V Michalarea, M Fontes, M Luken, T Avaiya, A Petruckevitch, D Flohr, J Hanwell, D Papadatos-Pastos, J Lopez, T Yap, J S. De Bono, and U Banerji. Incidence, severity and factors associated with diarrhoea in phase I oncology studies: experience of 1002 consecutive cases. Journal of Clinical Oncology 2016 34:15_suppl, 2568-2568 
  • A. Constantinidou, D. Krikelis, D. Olmos, M Scurr, RL Jones, S Ashley, IR Judson. Early assessment of MCV can predict clinical outcome in patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib. June 12: ASCO Annual Meeting, Chicago, Illinois, USA. J Clin Oncol 30: 2012 (suppl; abstr 10086)
  • R. Sanfilippo, A. Constantinidou, R. Bertulli, P. Coco, E. Fumagalli, M. Scurr, C. Morosi, S. Pilotti, I. R. Judson, P. G. Casali. Well-differentiated/dedifferentiated liposarcoma (WD/DD) and myxoid round cell/liposarcoma (MRCL) have differential sensitivity to high dose ifosfamide: combined analysis from two european referral institutions. June 11: ASCO Annual Meeting, Chicago, Illinois, USA. J Clin Oncol 29: 2011 (suppl; abstr 10023)
  • A Constantinidou, RL Jones, O Al-Muderis, K Thway, S Ashley, M Scurr, D R D’Adamo, ML Keohan, RG Maki, I R Judson. Chemotherapy in Clear Cell Sarcoma. ASCO Annual Meeting. Abstract No: 10098. Chicago, Illinois, USA, J Clin Oncol 28:15s, June 2010 (suppl; abstr 10098).
  • L. M. Pickering, A. Constantinidou, J. M. Larkin, S. A. Sohaib, P. Khatri, P. D. Nathan, A. Vinayan, T. Ferguson, S. St. Rose, M. E. Gore. Sunitinib treatment for longer than 2 years for renal cell carcinoma. ASCO Annual Meeting, Chicago, Illinois, USA, J Clin Oncol 28, June 2010 (suppl; abstr e15099)
  • A Constantinidou, R L Jones, M Scurr, O Al-Muderis, I Judson. The role of chemotherapy in aggressive fibromatosis. Sept 09: ESMO Berlin, Germany EJC suppl abstract book Vol 7 (2): 596, abstract no 9421
  • A Constantinidou, M Scurr, R Jones, O Al-Muderis, I Judson. Treatment of aggressive fibromatosis with pegylated liposomal doxorubicin: The Royal Marsden Hospital experience. ASCO Annual Meeting, Orlando, Florida, USA, J Clin Oncol 27:15s, May 2009 (suppl; abstr 10519)
  • A Constantinidou, SA Afuwape, T Hung, K Acland, C Healy, A-J Ramirez, M Harries. The role of PET scanning and sentinel node biopsy in melanoma: the patients’ perspective. Sept 08: ESMO Stockholm, Sweden, Annals of Oncology 19 (suppl 8): viii239 - viii246, 2008, abstract no 780P